The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia

Fibromyalgia is a chronic pain syndrome where current medications have limited efficacy and a slow onset of action. Esketamine shows potential as a rapid-acting analgesic, but previous low-dose studies failed to demonstrate long-term benefits. The efficacy of higher-dose ESK as an adjunctive therapy when standard treatments are insufficient remains unclear.

NCT Number	NCT07230171
Lead Sponsor	Beijing Tiantan Hospital Collaborators: Beijing Ditan Hospital, Beijing Sanbo Brain Hospital
Conditions	Fibromyalgia, Pregabalin, Esketamine
Enrollment	92 participants
Start Date	2025-09-15
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-07